# Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors

> **NCT05700669** · PHASE1,PHASE2 · COMPLETED · sponsor: **Valerio Therapeutics** · enrollment: 3 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer
- Recurrent Epithelial Ovarian Cancer
- Breast Cancer

## Interventions

- **DRUG:** AsiDNA
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT05700669
- **Lead sponsor:** Valerio Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-20
- **Primary completion:** 2023-10-31
- **Final completion:** 2023-10-31
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05700669

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05700669, "Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05700669. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*